NASDAQ:GALT Galectin Therapeutics (GALT) Stock Price, News & Analysis $2.81 -0.01 (-0.35%) (As of 10:54 AM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Galectin Therapeutics Stock (NASDAQ:GALT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Galectin Therapeutics alerts:Sign Up Key Stats Today's Range$2.76▼$2.8950-Day Range$2.47▼$3.0052-Week Range$1.55▼$4.27Volume33,560 shsAverage Volume145,310 shsMarket Capitalization$176.36 millionP/E RatioN/ADividend YieldN/APrice Target$11.00Consensus RatingBuy Company OverviewGalectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.Read More… 2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Galectin Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks34th Percentile Overall ScoreGALT MarketRank™: Galectin Therapeutics scored higher than 34% of companies evaluated by MarketBeat, and ranked 769th out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingGalectin Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageGalectin Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Galectin Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Galectin Therapeutics are expected to decrease in the coming year, from ($0.73) to ($1.65) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Galectin Therapeutics is -3.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Galectin Therapeutics is -3.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.76% of the float of Galectin Therapeutics has been sold short.Short Interest Ratio / Days to CoverGalectin Therapeutics has a short interest ratio ("days to cover") of 42.9, which indicates bearish sentiment.Change versus previous monthShort interest in Galectin Therapeutics has recently increased by 1.10%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGalectin Therapeutics does not currently pay a dividend.Dividend GrowthGalectin Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted12.76% of the float of Galectin Therapeutics has been sold short.Short Interest Ratio / Days to CoverGalectin Therapeutics has a short interest ratio ("days to cover") of 42.9, which indicates bearish sentiment.Change versus previous monthShort interest in Galectin Therapeutics has recently increased by 1.10%, indicating that investor sentiment is decreasing. News and Social Media1.7 / 5News Sentiment0.04 News SentimentGalectin Therapeutics has a news sentiment score of 0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Galectin Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for GALT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Galectin Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $18,846.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders52.70% of the stock of Galectin Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 11.68% of the stock of Galectin Therapeutics is held by institutions.Read more about Galectin Therapeutics' insider trading history. Receive GALT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Galectin Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address GALT Stock News HeadlinesGalectin Therapeutics (NASDAQ:GALT) Raised to Hold at StockNews.comNovember 20 at 3:20 AM | americanbankingnews.comGalectin Therapeutics presents three abstracts at AASLD 2024 Liver MeetingNovember 18 at 7:42 PM | markets.businessinsider.comBreaking News: Tesla headed to $500…That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. November 21, 2024 | WealthPress (Ad)Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver MeetingNovember 18 at 8:00 AM | globenewswire.comGalectin Therapeutics Inc. (NASDAQ: GALT) Shares Recent Updates in Latest 8-K FilingNovember 16, 2024 | americanbankingnews.comOptimistic Buy Rating for Galectin Therapeutics: Strategic Trial Design and Financial Stability Boost ProspectsNovember 15, 2024 | markets.businessinsider.comGalectin Therapeutics Reports Increased Q3 LossesNovember 15, 2024 | markets.businessinsider.comGalectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business UpdateNovember 14, 2024 | globenewswire.comSee More Headlines GALT Stock Analysis - Frequently Asked Questions How have GALT shares performed this year? Galectin Therapeutics' stock was trading at $1.66 at the start of the year. Since then, GALT stock has increased by 72.3% and is now trading at $2.86. View the best growth stocks for 2024 here. How were Galectin Therapeutics' earnings last quarter? Galectin Therapeutics Inc. (NASDAQ:GALT) posted its earnings results on Tuesday, August, 13th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by $0.04. Who are Galectin Therapeutics' major shareholders? Galectin Therapeutics' top institutional shareholders include Geode Capital Management LLC (1.38%), Ikarian Capital LLC, State Street Corp (0.40%) and Soltis Investment Advisors LLC (0.23%). Insiders that own company stock include James C Czirr, Kary Eldred, Kevin D Freeman, Richard A Jr Zordani, Jack W Callicutt, Joel Lewis, Fund LP 10X and Elissa J Schwartz. View institutional ownership trends. How do I buy shares of Galectin Therapeutics? Shares of GALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Galectin Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Galectin Therapeutics investors own include Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG). Company Calendar Last Earnings8/13/2024Today11/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GALT CUSIPN/A CIK1133416 Webwww.galectintherapeutics.com Phone(678) 620-3186Fax770-864-1327Employees9Year FoundedN/APrice Target and Rating Average Stock Price Target$11.00 High Stock Price Target$11.00 Low Stock Price Target$11.00 Potential Upside/Downside+290.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-41,070,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-163.15% Debt Debt-to-Equity RatioN/A Current Ratio1.13 Quick Ratio1.13 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.51) per share Price / Book-1.86Miscellaneous Outstanding Shares62,760,000Free Float29,686,000Market Cap$176.67 million OptionableOptionable Beta0.62 Social Links 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:GALT) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galectin Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galectin Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.